Tency [10], simple estimations of PCT based on day-to-day sampling could add components to facilitate comparisons and detection of trends. It would be beneficial to examine methods for validation, such as databases with delayed responses.More fileAdditional file 1: Table S1. Proportion by website of individuals still parasitaemic on Day 1, Day two, Day 3, and parasite clearance failure, ASAQ groups. Competing interests The authors declare that they have no competing interests. Authors’ contributions JZ and PO made the analysis, interpreted the information and prepared the manuscript. All authors read and approved the final manuscript. Acknowledgements We would prefer to thank all the individuals and employees at all trial web-sites who participated in these trials. We would like to thank Epicentre, Paris, France, for sharing the datasets [23,29-32,34-36] and each of the principal investigators of the other research. JZ received a grant from DNDi (Drugs for Neglected Ailments initiative) to accomplish this evaluation. DNDi sponsored 4 of the trials [19-22] but had no role within the style and conduct of your evaluation, interpretation of results of the manuscript. The Mali study was supported by European and Establishing Countries Clinical Trial Partnership (EDCTP) fellowship (Grant to AAD # 2004.2.C.f1) and by Sanofi Aventis (ARTEN-L-00848) who offered the monitoring services, the study insurance, the study drugs, as well as the biological parameters assessment machines.STING-IN-7 In Vitro Disclaimer PO is really a staff member of your WHO; the authors alone are responsible for the views expressed in this publication and they usually do not necessarily represent the choices, policy or views on the WHO. Author details 1 Drugs for Neglected Ailments Initiative (DNDi), Geneva, Switzerland. 2 Division of Medicine, University of California, San Francisco, CA, USA. 3 Division of Global Health (IHCAR), Division of Public Well being Sciences, Karolinska Institutet, Stockholm, Sweden. 4Disease Control and Elimination Theme, Health-related Study Council Unit, Banjul, The Gambia. 5Department of Parasitology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, S al. 6Malaria Other Parasitic Diseases Division-RBC, Ministry of Overall health, Rugenge, Kigali, Rwanda. 7Malaria Analysis and Instruction Center, Division of Epidemiology of Parasitic Ailments, Faculty of Medicine and Pharmacy, University of Science, Techniques and Technologies of Bamako, Bamako, Mali. 8 Institut de Recherche pour le D eloppement (IRD) Unitmixte de Recherche 198, Dakar BP 1386, S al. 9Centre National de Recherche et de Formation sur le Paludisme, Minist e de la Sant Ouagadougou, Burkina Faso. 10UNICEF/UNDP/WB/WHO Unique Programme for Analysis Training in Tropical Illnesses (TDR), Geneva, Switzerland.Hispidin web 11Centre for Tropical Medicine and Vaccinology, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK.PMID:24318587 Received: 17 January 2014 Accepted: 11 March 2014 Published: 25 MarchZwang et al. Malaria Journal 2014, 13:114 http://www.malariajournal/content/13/1/Page 10 ofReferences 1. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM: Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012, 12:85158. 2. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Trip.